Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies.
about
A transposon and transposase system for human applicationThe Sleeping Beauty transposon system: a non-viral vector for gene therapyNovel immunotherapies in lymphoid malignanciesT-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effectCARs in chronic lymphocytic leukemia -- ready to driveImmunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapiesCD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic LeukaemiaNovel therapeutic approaches for various cancer types using a modified sleeping beauty-based gene delivery systemDNA transposon-based gene vehicles - scenes from an evolutionary drivepiggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses.Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignanciesThe hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptorCombining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Translating Sleeping Beauty transposition into cellular therapies: victories and challenges.Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cellsImmunotherapy of human cancers using gene modified T lymphocytes.Unexpectedly high copy number of random integration but low frequency of persistent expression of the Sleeping Beauty transposase after trans delivery in primary human T cells.The impact of cHS4 insulators on DNA transposon vector mobilization and silencing in retinal pigment epithelium cells.Inhibition of angiogenesis and suppression of colorectal cancer metastatic to the liver using the Sleeping Beauty Transposon SystemThe promise and potential pitfalls of chimeric antigen receptors.MicroRNA-146a and microRNA-146b regulate human dendritic cell apoptosis and cytokine production by targeting TRAF6 and IRAK1 proteinsIGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.Sleeping Beauty transposon system for genetic etiological research and gene therapy of cancers.Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity.Efficient sleeping beauty DNA transposition from DNA minicircles.Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood.Role of microRNAs in lung development and pulmonary diseasesAdoptive immunotherapy: good habits instilled at youth have long-term benefits.Immunotherapeutic approaches for gliomaHighlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting.Treatment of lymphoma with adoptively transferred T cells.Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunityGenome-wide mapping of PiggyBac transposon integrations in primary human T cells.Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?".Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.Genetic redirection of T cells for cancer therapy.
P2860
Q24630047-37DFB15B-07F7-419C-8313-BCDA93BC03C3Q24633847-D6804EEE-4A37-417A-B8A3-EDED53237171Q26777394-D8C933D3-BFF0-45EA-BE36-18C7B689E167Q26826830-E1CC91EC-C5A6-4206-ACAE-F2F2B3CDD7EFQ26830526-BD18717C-D32C-44D5-AE86-591B364AE4FAQ27027243-78540763-4B95-4065-89AA-6C453346CFBDQ28081600-AD7AE0DA-DA7A-4D38-86E3-09E825EA3B94Q28660424-4B69CCCC-65F2-46A7-B9E7-80607C3F82D2Q28660891-740C8E5B-CF59-456D-BAE7-933BA0313330Q30496580-32DF610E-ED15-4D81-841B-608FE06ED43AQ30667174-9845055C-62B8-4C62-8338-65CAF75FE877Q33564364-AC7181A4-821F-486C-893E-ACEE0478DAE3Q33819935-7CDC12D1-6749-4409-ACD9-CB3DBC88FC11Q33852140-259D1FE2-60C3-4A9A-A7E0-E4939C56B220Q33862876-9D295598-FBE3-408E-ADFD-F2FA2AE03D30Q34122292-B7E3BBB5-1ABC-4217-BABC-22CFE7A068F0Q34127579-F88E0F7C-17AD-4488-AC06-C53EB208E045Q34183381-A23B6B51-5AD3-4299-98C6-8F76F9935F3FQ34188383-2C43D41A-F9C5-4AD8-ACEF-48C33254817BQ34399240-375543F6-7DC4-4C4E-945D-D73F666393ADQ34461198-113391F4-E29A-421C-9C99-255FD75082F9Q34608072-E55DAE5A-B70A-4541-9EA4-E4E325F4F177Q34970378-FCCC11D5-6651-48BB-A3D7-493FA801C137Q35048883-453BDC5C-1DAA-4FBF-BE2F-814AE3E074C7Q35690979-2796A2C9-3764-44B1-978B-A7A2A8F9AD34Q35980893-D80448BE-1595-4D10-88ED-980BDE550CE3Q36214663-237E301D-1442-4E91-AAD8-3BD7A0957801Q36311669-221EB000-13E1-4C9D-9ED9-57CF716F0E11Q36652377-808A52F0-55B4-49A4-BE4D-FF4648EF99EDQ36682812-12644754-E7DC-4D8E-9990-B532060C18A8Q37133793-0F7EF4F6-3E63-4581-8097-4BA1E7837CFFQ37257225-5F88A691-92D0-4504-840E-E53D1C7D3F59Q37267793-F186E511-DE78-4523-95F8-997030F20F26Q37271276-D91351A5-1427-4170-A2ED-9CEDB17EE384Q37419728-BF668C16-D75B-4297-B266-2DD33874A94AQ37469199-ED1AC713-FCD1-4157-8433-506D57525019Q37485093-0283A6DB-A4B5-4AAB-B7CD-B639E2F2A4C1Q37585288-02765984-81C9-46F6-8041-BD254E37A317Q37588329-1C6A8A8F-3BAB-483F-AA54-D8C1631C4F0DQ37697337-E2474AA5-2B7E-4649-813B-881FAD4597EB
P2860
Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Sleeping Beauty transposon-med ...... f CD19+ lymphoid malignancies.
@ast
Sleeping Beauty transposon-med ...... f CD19+ lymphoid malignancies.
@en
type
label
Sleeping Beauty transposon-med ...... f CD19+ lymphoid malignancies.
@ast
Sleeping Beauty transposon-med ...... f CD19+ lymphoid malignancies.
@en
prefLabel
Sleeping Beauty transposon-med ...... f CD19+ lymphoid malignancies.
@ast
Sleeping Beauty transposon-med ...... f CD19+ lymphoid malignancies.
@en
P2093
P2860
P356
P1433
P1476
Sleeping Beauty transposon-med ...... f CD19+ lymphoid malignancies.
@en
P2093
Bruce L Levine
Carl H June
Christopher J Lees
Hongfeng Guo
John E Wagner
Johnthomas Kang
Michael Milone
R Scott McIvor
Syam Tammana
P2860
P304
P356
10.1038/SJ.MT.6300404
P577
2008-01-29T00:00:00Z